Item 2.02 Results of Operations and Financial Condition.
On May 3, 2016, Nektar Therapeutics, a Delaware corporation ("Nektar"), issued a
press release (the "Press Release") announcing its financial results for the
quarter ended March 31, 2016. A copy of the Press Release is furnished herewith
as Exhibit 99.1.
On April 28, 2016, Nektar announced that it would hold a Webcast conference call
on May 3, 2016 to review financial results for the quarter ended March 31, 2016.
This conference call is accessible through a link that is posted on the home
page and Investor Relations section of the Nektar website:
The information in this report, including the exhibit hereto, is being furnished
and shall not be deemed "filed" for purposes of Section 18 of the Securities
Exchange Act of 1934, as amended, or otherwise subject to the liabilities of
that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as
amended. The information contained herein and in the accompanying exhibit shall
not be incorporated by reference into any filing with the Securities and
Exchange Commission made by Nektar Therapeutics, whether made before or after
the date hereof, regardless of any general incorporation language in such
Item 9.01 Financial Statements and Exhibits.
99.1 Press Release titled "Nektar Therapeutics Reports Financial Results
for the First Quarter of 2016" issued by Nektar Therapeutics on May 3,
© Edgar Online, source Glimpses